{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:30:56Z","timestamp":1787682656467,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T15:27:58Z","timestamp":1671550078000},"page":"407-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3998","authenticated-orcid":false,"given":"Erica A.","family":"Roesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Bonfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5607","authenticated-orcid":false,"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-0097","authenticated-orcid":false,"given":"Jay","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gluvna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-8004","authenticated-orcid":false,"given":"Elliot","family":"Dasenbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold I.","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-4693","authenticated-orcid":false,"given":"James F.","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcf.2022.12.001_bib0001","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/ajrccm.154.5.8912731","article-title":"Cystic fibrosis","volume":"154","author":"Davis","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 40","key":"10.1016\/j.jcf.2022.12.001_bib0002","first-page":"S39","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.001_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1011080229374","article-title":"Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells","volume":"25","author":"Stecenko","year":"2001","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.001_bib0004","doi-asserted-by":"crossref","first-page":"L493","DOI":"10.1152\/ajplung.2001.280.3.L493","article-title":"Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines","volume":"280","author":"Kube","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.001_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.001_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.1144","article-title":"Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis","volume":"32","author":"Rosenfeld","year":"2001","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.001_bib0007","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201708-1616OC","article-title":"Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets","volume":"197","author":"Rosen","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"S3","key":"10.1016\/j.jcf.2022.12.001_bib0008","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: an update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"19","key":"10.1016\/j.jcf.2022.12.001_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.001_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2022.12.001_bib0011","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.12.001_bib0012","first-page":"334","article-title":"Six-year follow-up of ivacaftro-treated subjects with CFTR-G551D: an update on the Dublin cohort","volume":"54","author":"Durfey","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2022.12.001_bib0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/01902148.2013.816803","article-title":"Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell","volume":"39","author":"Inamdar","year":"2013","journal-title":"Exp Lung Res"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.001_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010020","article-title":"Lights and shadows in the use of mesenchymal stem cells in lung inflammation, a poorly investigated topic in cystic fibrosis","volume":"9","author":"Caretti","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2022.12.001_bib0015","article-title":"Optimization of human mesenchymal stem cells for rheumatoid arthritis: implications for improved therapeutic outcomes","author":"Breitman","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jcf.2022.12.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100742","article-title":"Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?","volume":"46","author":"Hamdan","year":"2021","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.jcf.2022.12.001_bib0017","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/stem.544","article-title":"Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37","volume":"28","author":"Krasnodembskaya","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcf.2022.12.001_bib0018","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/emm.2013.94","article-title":"Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.001_bib0019","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/sctm.21-0021","article-title":"Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells","volume":"10","author":"Wang","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcf.2022.12.001_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4236\/scd.2013.32019","article-title":"Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease","volume":"3","author":"Bonfield","year":"2013","journal-title":"Stem Cell Discovery"},{"key":"10.1016\/j.jcf.2022.12.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5303048","article-title":"Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment","volume":"2016","author":"Sutton","year":"2016","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.jcf.2022.12.001_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.573065","article-title":"Enhancing cystic fibrosis immune regulation","volume":"12","author":"van Heeckeren","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.001_bib0023","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7633.1000400","article-title":"Mesenchymal stem cell soluble mediators and cystic fibrosis","volume":"7","author":"Sutton","year":"2017","journal-title":"J Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.jcf.2022.12.001_bib0024","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/sctm.20-0521","article-title":"Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium","volume":"10","author":"Bonfield","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"10.1016\/j.jcf.2022.12.001_bib0026","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jcyt.2021.04.009","article-title":"Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells","volume":"23","author":"Viswanathan","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcf.2022.12.001_bib0027","unstructured":"http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"issue":"10","key":"10.1016\/j.jcf.2022.12.001_bib0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.001_bib0029","doi-asserted-by":"crossref","first-page":"L908","DOI":"10.1152\/ajplung.00218.2020","article-title":"Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells","volume":"319","author":"Abreu","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2022.12.001_bib0030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fphar.2020.00654","article-title":"Biological considerations in scaling up therapeutic cell manufacturing","volume":"11","author":"Cherian","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:39Z","timestamp":1761601659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322014217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199322014217"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}